Moderna lays out an oncology-driven growth plan at its 2026 Analyst Day, Pfizer and Blackstone sign a co-funding deal worth up to $1.5 billion for berobenatide, and Parexel’s Stacy Hurt on how patients’ use of AI is reshaping sponsor communication.
Feature|Videos|September 9, 2026
How ClaimGuardRx's Purpose-Built AI Detects and Counters Diversion Tactics
Author(s)Bryan Dennison, Paysign
Key Takeaways
- Recognize what makes ClaimGuardRx's proprietary, domain-specific LLM different from repurposed fraud tools.
- Understand how the platform's detect-and-respond design shortens the time between spotting a threat and acting on it.
Bryan Dennison breaks down the purpose-built technology behind ClaimGuardRx and how its detect-and-respond design keeps manufacturers ahead of evolving diversion tactics.
Advertisement
Sponsored by Paysign
Bryan Dennison, Senior Vice President of Sales and Product at Paysign, explains the technical foundation of ClaimGuardRx, a proprietary large language model (LLM) trained specifically on patient affordability claim patterns rather than adapted from a general-purpose model. He covers how the platform's voice-driven interface lets nontechnical users ask plain-language questions and receive analytical insights, supporting data, and recommended next actions in seconds.
Dennison also highlights what he considers the platform's true differentiator: its ability to close the loop by not just detecting maximizer activity, but helping teams design and deploy counter-algorithms in response. He also shares Paysign's product roadmap, from expanding detection coverage to building toward a multimodal, agentic platform.
Advertisement
Related to this article
Moderna used its 2026 Analyst Day to outline an oncology-driven growth strategy anchored by intismeran and other cancer antigen therapies.
Pfizer and Blackstone Life Sciences sign a co-funding deal in which Blackstone is set to provide up to $1.5 billion through 2028 to advance berobenatide.
With 60% of Americans using AI health tools, patient advocates are encouraging collaborative use of AI alongside healthcare teams for better outcomes.
FDA approves Merck KGaA’s Pimjetmi for tenosynovial giant cell tumor, Parexel’s Stacy Hurt on when patient input should enter the clinical research process, and Ignite Proteomics’ Dr. Brian Corgiat on adjusting for tumor mutations in treatment decisions.
FDA has approved Merck KGaA’s Pimjetmi, an oral CSF-1R inhibitor, for adults with symptomatic tenosynovial giant cell tumors.
AI can make clinical trials smarter and faster, but lived patient experience remains irreplaceable in guiding research toward optimal results.
FDA approves Bayer’s asundexian as the first Factor XIa inhibitor for secondary stroke prevention, the FDA requires a new safety label warning across all GLP-1 receptor agonists for a potential NAION risk, and AstraZeneca acquires Omniose to add a bioconjugation platform to its vaccine pipeline.
Advertisement
Advertisement
Trending on PharmExec
1
Building Connected AI Ecosystems, Not Standalone Tools
2
Pfizer and Blackstone Sign Co-Funding Deal for berobenatide
3
Where AI Is Having the Most Impact and Where Gaps Remain
4
Moderna Lays Out Oncology-Driven Growth Plan at 2026 Analyst Day
5